InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

- Current share price for NOX : $0.086

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 HERACLES clinical trial Update 3 25 Aug 2025 9:30AM $0.115 $0.086 fallen by 25.22%
$26 HERACLES clinical trial Update 2 11 Aug 2025 8:31AM $0.110 $0.086 fallen by 21.82%
$26 US company demonstrates strong Sofra potential 5 Aug 2025 8:28AM $0.115 $0.086 fallen by 25.22%
$26 June 2025 Quarterly Activities Report and Appendix 4C 30 Jul 2025 8:30AM $0.125 $0.086 fallen by 31.20%
$26 HERACLES clinical trial - Update 1 28 Jul 2025 9:39AM $0.075 $0.086 risen by 14.67%
$26 First SOF-SKN dose in HERACLES clinical trial 16 Jul 2025 8:14AM $0.048 $0.086 risen by 79.17%
$26 Clinical trial recruitment progressing rapidly 25 Jun 2025 10:08AM $0.051 $0.086 risen by 68.63%
$26 Promising Sofra results from overseas company 11 Jun 2025 11:11AM $0.066 $0.086 risen by 30.30%
$26 Green light for HERACLES clinical trial 29 May 2025 8:37AM $0.066 $0.086 risen by 30.30%
$26 NYR: Notice of Ceasing to be a Substantial Holder - NOX 21 May 2025 8:21AM $0.068 $0.086 risen by 26.47%
$26 Notice of Change of Interests of Substantial Holder for NYR 20 May 2025 9:29AM $0.068 $0.086 risen by 26.47%
$26 NYR: Corporate Update 20 May 2025 9:20AM $0.068 $0.086 risen by 26.47%
$26 New funds from Nyrada share sales 20 May 2025 8:48AM $0.068 $0.086 risen by 26.47%
$26 SOF-SKN data presented at rheumatology conference 6 May 2025 8:24AM $0.080 $0.086 risen by 7.50%
$26 Noxopharm clinical trial submission 2 May 2025 8:45AM $0.077 $0.086 risen by 11.69%
$26 March 2025 Quarterly Activities Report and Appendix 4C 30 Apr 2025 8:55AM $0.077 $0.086 risen by 11.69%
$26 SOF-SKN successfully passes final pre-trial study 15 Apr 2025 8:22AM $0.069 $0.086 risen by 24.64%
$26 Noxopharm expands collaboration with Hudson Institute 25 Mar 2025 8:49AM $0.087 $0.086 fallen by 1.15%
$26 Doherty Clinical Trials to host HERACLES trial 12 Mar 2025 10:10AM $0.072 $0.086 risen by 19.44%
$26 Appendix 4D and FY2025 Half Year Financial Report 25 Feb 2025 1:38PM $0.091 $0.086 fallen by 5.49%
$26 SOF-SKN passes required in vitro safety tests 4 Feb 2025 8:17AM $0.085 $0.086 risen by 1.18%
$26 December 2024 Quarterly Activities Report and Appendix 4C 29 Jan 2025 8:17AM $0.100 $0.086 fallen by 14%
$26 Notice under s708A(12C)(e) of the Corporations Act 2001 10 Jan 2025 4:29PM $0.083 $0.086 risen by 3.61%
$26 Notification regarding unquoted securities - NOX 10 Jan 2025 4:25PM $0.083 $0.086 risen by 3.61%
$26 Notification regarding unquoted securities - NOX 10 Jan 2025 4:22PM $0.083 $0.086 risen by 3.61%

51 - 75 of 793 results

Page 3 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.